NOVARTIS’ PAY-OUT APPEAL LESS IN DEMAND, FOR NOW (ADD; 8% UPSIDE)
21/12/20 -"2020 ridiculed various market notions, including the long-held principle of defensive investing in turbulent times. Hence, year-to-date, the Pharma sector lost 0.9% in value, which was not far away ..."
Pages
64
Language
English
Published on
21/12/20
You may also be interested by these reports :
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...
28/01/26
2025 was a year of US tariff threats and drug pricing pressure on the pharma industry, and for AstraZeneca (REDUCE; UK), it started under the cloud ...